SEATTLE, WASHINGTON — (Marketwire) — 06/09/12 — VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT)(OTCQX:VPTDF) is pleased to announce that Mayo Clinic has joined its multi-centre clinical trial to evaluate the use of an ultrasound diagnostic tool (the VMS(TM) heart analysis system) for patients with pulmonary arterial hypertension (PAH). Robert Frantz, M.D., a consultant in the Cardiovascular Division and Associate Professor of Medicine, College of Medicine, Mayo Clinic is the lead investigator for the clinical trial site in Rochester, MN.

      The VMS(TM) is for investigational use only in the United States and is approved for sale and clinical use in Canada and Europe. VentriPoint is pursuing US-FDA approval through the 510(k) process.

      About VentriPoint Diagnostics Ltd.

      VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure.

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

      VentriPoint Diagnostics Ltd.
      Dr. George Adams, CEO
      (206) 283-0221, ext. 401

      Howard Group Inc.
      David Burwell, Investor Relations
      1.888-221-0915 or 403-221-0915